Genmab: Phase 3 study started recruiting, 600 planned (Colorectal Cancer)
2026-11-03
GlaxoSmithKline: Phase 3 study started recruiting, 610 planned (Neoplasms, Endometrial)
2026-11-03
Merck Sharp & Dohme LLC: Phase 3 study started recruiting, 1104 planned (Diabetic Retinopathy, Macular Edema)
2026-11-03
NervGen Pharma: Phase 3 study started recruiting, 150 planned (Chronic Spinal Cord Injury)
2026-11-03
Nurix Therapeutics, Inc.: Phase 2 study started recruiting, 150 planned (B-cell Lymphoma, Chronic Lymphocytic Leukemia)
2026-11-03
Public records via
ClinicalTrialStartPulse
on Zalwin. Informational only.